A ccumulation of eosinophils is observed in a variety of human diseases, including asthma and allergic rhinitis, and is considered to play a key role in pathogenesis of these conditions (1) (2) . The mechanism of eosinophil migration into tissues from the vasculature has been studied by several laboratories (3) (4) (5) . Eosinophil recruitment to sites of allergic inflammation is believed to be dependent on the local production of eosinophil-priming cytokines (e.g., IL-3, GM-CSF, and IL-5) (6, 7), endothelial-activating cytokines (e.g., IL-1␤, TNF-␣, IL-4, and IL-13) (8 -11) , and C-C chemokines (e.g., eotaxin, eotaxin-2, RAN-TES, monocyte chemotactic protein-3 (MCP-3), 3 and MCP-4) (12) (13) (14) (15) (16) (17) . To study eosinophil recruitment, in vitro models of chemotaxis, adhesion, and transendothelial migration (TEM) have been developed (8, 9, 18 -22) . Studies using an in vitro model of TEM have established that eosinophil migration across endothelial cell monolayers is induced after activation of endothelial cells with IL-1␤, TNF-␣, or IL-4 (8, 9, 20 -22) . This process is disrupted by single Abs directed against ␤2 integrins on the surface of the eosinophils or by a cocktail of Abs against several endothelial adhesion molecules (VCAM-1, ICAM-1, and E-selectin) (8) . Eosinophil-activating cytokines, (e.g., IL-3, IL-5, and GM-CSF) also potentiate eosinophil TEM; eosinophils purified from the lungs of allergic volunteer subjects who underwent experimental Ag challenge display a similarly potentiated TEM response (9) .
Numerous chemokines have been identified that have the ability to cause selective eosinophil migration, including RANTES, MCP-3, MCP-4, macrophage-inflammatory protein-1␣, eotaxin-1, eotaxin-2, and macrophage-derived chemokine (14 -17, 23-28) . Studies in humans and animals indicate that MCP-3, RANTES, and eotaxin are all present at significantly increased levels in either airways or skin of allergic subjects after allergen challenge (29 -31) . In vivo challenge models using RANTES or eotaxin have resulted in an eosinophil-rich inflammatory infiltrate in both animals (32) and humans (33, 34) . Furthermore, the expression of these chemokines is associated with the accumulation of eosinophils at the sites of allergic inflammation (12, (35) (36) (37) . The importance of several chemokines in eosinophil recruitment has been demonstrated by in vivo studies in which neutralizing Abs to chemokines or their receptors blocked eosinophil trafficking to sites of inflammation (38 -40) .
The integrated roles of cytokines and chemokines during the process of eosinophil TEM remain unclear. Several studies with neutrophils indicate that there is often a synergism between a leukocyte-activating cytokine, e.g., GM-CSF, and a chemoattractant such as f-Met-Leu-Phe (41, 42) . Recent reports have suggested a cooperation between IL-5 and eotaxin during eosinophil accumulation in animal models, which is reminiscent of what we observed in vitro in the TEM assay (18, 43) . Although endothelial-activating cytokines, eosinophil-activating cytokines, and C-C chemokines each have the ability to induce eosinophil migration across endothelium, the magnitude of the response is likely to depend on the combination of these stimuli. In the present study, we have investigated the roles played by the priming cytokine IL-5, the endothelial activators IL-1␤ or TNF-␣, and several C-C chemokines, independently and in concert. Using the in vitro TEM model, we demonstrate that eotaxin, eotaxin-2, MCP-4, and RANTES induce eosinophil TEM. Activation of endothelial cells by cytokines such as IL-1␤ or TNF-␣ or priming of eosinophils by IL-5 both promote CCR3-dependent migration of eosinophils across an endothelial monolayer in conjunction with these chemokines.
Materials and Methods

Monoclonal Abs
Anti-human CCR3 mAb (7B11; IgG2a), which selectively blocks CCR3 (44) , and anti-human CCR1 mAb (2D4; IgG1) were produced by LeukoSite (Cambridge, MA). F(abЈ) 2 preparation of mAb recognizing very late Ag (VLA)-4 (HP2/1; IgG1; Immunotech, Minneapolis, MN), ␣D␤2 (240I; IgG1; ICOS, Bothell, WA), E-selectin (ENA 2; IgG1; Caltag Laboratories, Burlingame, CA), and platelet endothelial cell adhesion molecule (PE-CAM)-1 (CD31) (IP-66; IgG1; Centocor, Malvern, PA) were used as blocking Abs. A mAb against HLA class I (W6/32; IgG2a; Becton Dickinson, Mountain View, CA; and 12D10; IgG1; Centocor, Malvern, PA) were used as a negative control.
Endothelial cell cultures
Human umbilical vein endothelial cells (HUVEC) were isolated and cultured according to the methods described by Jaffe et al. (45) with some modifications (8) . HUVEC (2 ϫ 10 4 cells) from the first or second passage were cultured on 2% gelatin-coated Transwell culture inserts (6.5-mm diameter polycarbonate membranes with 5-mm pores; Costar, Cambridge, MA) according to the method of Morzycki et al. (8, 46) . Endothelial cell culture medium (0.2 ml M199; Life Technologies, Grand Island, NY) supplemented with 20% FCS, 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 U/ml) (Life Technologies), endothelial cell growth supplement (20 g/ml; Collaborative Research, Bedford, MA), and heparin sodium (90 g/ml; Sigma, St. Louis, MO) was added to the Transwell inserts only. To confirm the confluency of the HUVEC on the membrane, sample monolayers were routinely stained with Diff-Quik (American Scientific Products, McGraw Park, IL) before use in experiments.
Purification of eosinophils
Human eosinophils were isolated from EDTA-anticoagulated venous blood of normal donors or patients with asymptomatic allergic rhinitis or asthma by percoll (1.090 g/ml) gradient centrifugation at room temperature. After centrifugation, all procedures were conducted at 4°C to prevent cell activation. RBCs were removed by hypotonic lysis before removal of CD16-positive cells (neutrophils) using immunomagnetic beads (Dynal, Oslo, Norway) (8, 47) . Eosinophil purity (based on examination of Diff Quikstained cytocentrifugation preparations) was 98 Ϯ 1%, and viability (erythrosin B dye exclusion) was 99 Ϯ 1% (n ϭ 30). Eosinophils were labeled with 51 Cr, washed extensively, and resuspended (2 ϫ 10 6 /ml) in enriched medium (M199 medium supplemented with 20% FCS, antibiotics, and L-glutamine).
Transendothelial migration assay
The TEM assays were performed as previously reported with some modification (8) . HUVEC monolayers grown in Transwell inserts were pretreated for 4 h with indicated concentrations of human rIL-1␤ (R&D Systems, Minneapolis, MN), human rTNF-␣ (R&D Systems), or culture medium (control) and then were rinsed twice with PAGCM buffer (PIPES buffer (25 mM PIPES, 110 mM NaCl, 5 mM KCl, pH 7.4) containing 0.003% human serum albumin, 0.1% D-glucose, and 1 mM each of MgCl 2 and CaCl 2 (Sigma). These treatments did not change the state of confluence, as determined by microscopic examination of Diff-Quik-stained filters. Enriched medium (0.6 ml) with or without eotaxin, eotaxin-2, MCP-4, or RANTES (R&D Systems) was added to the wells of a 24-well plate, and 0.1 ml of eosinophil suspension was added to each chamber before immersion of the Transwell chamber. In experiments to examine the effects of IL-5 on spontaneous or chemokine-induced eosinophil TEM across resting, IL-1␤, or TNF-␣-stimulated HUVEC, 51 Cr-labeled eosinophils were incubated with 5 ng/ml of IL-5 for 30 min at 37°C before being added along with IL-5 to the upper chamber. The effect of blocking Abs on TEM was examined by preincubating 51 Cr-labeled eosinophils with 10 g/ml anti-CCR3, 2 g/ml anti-VLA-4, 220 g/ml anti-␣D␤ 2 , or 10 g/ml anti-HLA in enriched medium at 4°C for 30 min and then adding cells to the upper chamber along with the medium containing the Ab. To evaluate the effect of anti-PECAM-1 Ab on TEM, HUVEC were treated with anti-PECAM Ab (10 g/ml), or 12D10 (10 g/ml) at 37°C for 30 min before 51 Crlabeled eosinophils were placed in the upper chamber. In all experiments, TEM was allowed to proceed for 2 h, after which nonadherent cells in the upper chamber were removed. The undersurface of the filter was rinsed with 0.6 ml ice-cold PAG (PIPES buffer with 0.003% human serum albumin and 0.1% D-glucose) containing 5 mM EDTA to dislodge adherent transmigrated cells. The cells that had migrated and fallen into the lower chamber were combined with those detached from the filter and 51 Cr radioactivity was determined. All determinations were conducted in triplicate. Migration was calculated as follows: [(cpm migrated)/(total cpm added)] ϫ 100. Background eosinophil TEM was less than 5% in all experiments; this was subtracted from the total and the values are expressed as net TEM unless indicated otherwise.
Statistical analysis
The results are presented as mean Ϯ SEM. The statistical significance of differences between groups was determined using Student's (two-tailed) unpaired t test.
Results
The ability of several C-C chemokines to induce TEM of eosinophils was assessed. As shown in Fig. 1 , the C-C chemokines eotaxin, eotaxin-2, MCP-4, and RANTES induced eosinophil TEM across resting HUVEC. The results showed a concentrationdependent increase in eosinophil migration with the following rank order of potency: eotaxin Ϸ eotaxin-2 Ͼ MCP-4 Ϸ RANTES (maximun TEM: 41.5 Ϯ 0.9% for eotaxin at 100 ng/ml; 38 Ϯ 3.6% for eotaxin-2 at 100 ng/ml; 21 Ϯ 3.5% for MCP-4 at 500 ng/ml; and 20 Ϯ 2.3% for RANTES at 500 ng/ml). In addition to the fact that RANTES and MCP-4 were less potent, they also appeared to produce a lower maximal response than the CCR3-specific chemokines eotaxin and eotaxin-2 did. The CXC chemokines IL-8 (100 ng/ml) and growth-related oncogene-␣ (100 ng/ml) did not induce eosinophil TEM (data not shown). Similar experiments were performed in Transwell chambers without the presence of an endothelial monolayer. In these experiments, the potencies were similar to those in Fig. 1 , but the maximal responses for the four chemokines were similar to each other (i.e., 20.0 Ϯ 1.0 and 19.5 Ϯ 0.5 for eotaxin and eotaxin-2 at 100 ng/ml, and 18.5 Ϯ 3.5 and FIGURE 1. Effect of C-C chemokines on eosinophil TEM. HUVEC were grown as confluent monolayers on polycarbonate Transwell inserts. Indicated C-C chemokines were placed in the lower chamber. 51 Cr-labeled eosinophils were placed in the upper chamber and transendothelial migration of eosinophils was determined after a 2-h incubation at 37°C in a 5% CO 2 incubator as described in Materials and Methods. Data shown are net TEM after subtracting baseline (Ͻ5%) and represent mean Ϯ SEM from at least three experiments. 16 .5 Ϯ 0.5 for RANTES and MCP-4 at 500 ng/ml; n ϭ 2). These results indicate that the differences in maxima seen in Fig. 1 are dependent upon the presence of an endothelial monolayer.
Activation of HUVEC for 4 h with IL-1␤ or TNF-␣ induced modest eosinophil TEM in a concentration-dependent manner. IL-1␤ was ϳ100-fold more potent than TNF-␣, with the maximum eosinophil TEM at 1 ng/ml for IL-1␤ (10 Ϯ 1.5%) and Ն100 ng/ml for TNF-␣ (5.9 Ϯ 1.3%) (Fig. 2) . The possibility of these findings being due to endotoxin contamination was ruled out by using polymixin B (up to 100 g/ml), which had no effect on IL-1␤-or TNF-␣-induced eosinophil TEM, whereas LPS-induced (1 g/ml) eosinophil TEM was completely inhibited by polymixin B (50 g/ml) (data not shown). To test the influence of endothelial activation with IL-1␤ or TNF-␣ on chemokine-induced eosinophil TEM, we first treated the HUVEC with various concentrations of these cytokines for 4 h before assay. IL-1␤ or TNF-␣-induced TEM of eosinophils was enhanced synergistically by the addition of eotaxin or RANTES to the lower chamber (Figs. 3 and 4) . Synergy was observed using a submaximal concentration of each chemokine (10 ng/ml of eotaxin and 100 ng/ml of RANTES; see Fig. 1 ). Eosinophil TEM across both TNF-␣-and IL-1␤-treated HUVEC was increased by 2-to 3-fold in the presence of either eotaxin or RANTES. The maximal response was observed at a concentration of IL-1␤ of 0.1 ng/ml and a concentration of TNF-␣ of Ն100 ng/ml.
The eosinophil chemotactic responses to eotaxin and RANTES have been shown to be mediated by the CCR3 receptor (14, 44) . Treatment of eosinophils with anti-CCR3 (10 g/ml) but not anti-HLA completely blocked eosinophil TEM across resting HUVEC induced by eotaxin, MCP-4, and RANTES (Fig. 5) . In two separate experiments, eotaxin-2-induced eosinophil TEM across resting HUVEC was also completely inhibited by anti-CCR3 Ab (data not shown). Anti-CCR3 also inhibited TEM across TNF-␣-stimulated (25 ng/ml) HUVEC when eotaxin was present in the lower chamber (n ϭ 3; 7.7 Ϯ 1.7% TEM with anti-CCR3 vs 53.7 Ϯ 3.25% control) (Fig. 6 ). Anti-CCR3 or anti-HLA had no inhibitory effect on eosinophil TEM across resting HUVEC or HUVEC activated by TNF-␣ in the absence of eotaxin or RANTES (data not shown). Anti-HLA Ab, used as a negative control, did not inhibit eotaxin-induced eosinophil TEM across either resting or TNF-␣-stimulated HUVEC (Fig. 6) .
The role of cell adhesion molecules during TEM was evaluated by using various mAbs. Preincubation of eosinophils with anti-VLA-4 and anti-␣D␤ 2 had no significant effect on eosinophil TEM across either resting or TNF-␣-activated HUVEC (Fig. 7A) . Similarly, treatment of HUVEC monolayers with anti-E selectin before TEM assay showed no difference in eosinophil transmigration compared with control (data not shown). In contrast, preincubation of HUVEC with anti-PECAM significantly inhibited eotaxin-induced eosinophil TEM across TNF-activated HUVEC (38 Ϯ 2.0% TEM with anti-PECAM vs 59.1 Ϯ 4.7% control; n ϭ 4; p Ͻ 0.05) (Fig. 7B) .
We investigated eotaxin-induced eosinophil TEM across resting and IL-1␤-stimulated HUVEC in the presence or absence of eosinophil-active cytokine IL-5. The results showed synergy between IL-5 and eotaxin (12.5 Ϯ 3.5%, 14.3 Ϯ 5.2%, and 45.3 Ϯ 5.2% for IL-5 alone, eotaxin alone, and the combination of the two, respectively; n ϭ 3; p Ͻ 0.05 for the combination vs expected combined value). Similar results were found with RANTES (25 ng/ml) (12.5 Ϯ 3.5%, 5 Ϯ 1.1%, 26 Ϯ 5.5% for IL-5 alone, RANTES alone, and the combination of the two, respectively; n ϭ 3; p Ͻ 0.05)( Table I ). The combination of IL-5 with IL-1␤ yielded less than additive eosinophil TEM. Anti-CCR3 Ab had no inhibitory effect on IL-5-induced eosinophil TEM across resting HUVEC in the absence of added eotaxin or RANTES (Table I) . However, anti-CCR3 Ab appeared to inhibit eosinophil TEM across IL-1␤-treated HUVEC in the presence (47%) or absence (55%) of IL-5, but the inhibition was not statistically significant. Whether TEM induced by IL-1␤ involves a small amount of endothelial-derived CCR3-active chemokines requires further investigation. Anti-CCR1 (2D4) at 10 g/ml had no inhibitory effect on IL-1␤-, TNF-␣-, or IL-5-induced eosinophil TEM (data not shown).
Discussion
We have investigated the actions of some of the C-C chemokines that are known to be chemotactic for eosinophils in a TEM assay in the absence or presence of endothelial-activating and/or eosinophil-priming cytokines. Migration of human eosinophils across unstimulated endothelial cells in response to eotaxin, RANTES, FIGURE 4. Induction of eosinophil TEM across IL-1␤-stimulated HUVEC by chemokines. Endothelial cells were grown as a monolayer in Transwell inserts, stimulated for 4 h with medium or indicated concentrations of IL-1␤, and rinsed. 51 Cr-labeled eosinophils were placed in the upper chamber, and enriched medium 199 (control), eotaxin (10 ng/ml), or RANTES (100 ng/ml) was added to the lower compartment. Eosinophil TEM was determined and expressed as in Fig. 1 from at least three experiments. ‫,ء‬ p Ͻ 0.05 vs expected value (combined net values).
FIGURE 5.
Effect of the anti-CCR3 Ab 7B11 on C-C chemokine-induced eosinophil transendothelial migration. Indicated C-C chemokines (100 ng/ml) were placed in the lower chamber. 51 Cr-labeled eosinophils were preincubated with enriched medium, anti-CCR3 Ab (10 g/ml), or anti-HLA Ab (negative control) at 4°C for 30 min and then were placed in the upper chamber of the TEM assay. Eosinophil TEM was determined as in Fig. 1 . Data shown represent mean Ϯ SEM from three experiments in which control migration was 4.5 Ϯ 0.4%. ‫,ء‬ p Ͻ 0.05 vs control. macrophage-inflammatory protein -1␣, and MCP-3 has been demonstrated using an endothelial cell line (48) . We found a concentration-dependent increase in eosinophil TEM exhibited by the four chemokines tested with the following rank order of potency: eotaxin Ϸ eotaxin-2 Ͼ MCP-4 Ϸ RANTES. In the TEM assay we observed higher potency with the "pure" CCR3 agonists (eotaxin and eotaxin-2) than with those that bind to multiple receptors in addition to CCR3 (MCP-4 binds to CCR2 and RANTES binds to CCR1, CCR4, and CCR5). The pure CCR3 agonists appeared to have a higher efficacy or maximal effect (i.e., ϳ42% net TEM maximum response for eotaxin and eotaxin-2 compared with 22% for RANTES and MCP-4; see Fig. 1 ). The underlying mechanism explaining these interesting differences is unknown. Variations in potency among different chemokines have been described by several investigators using standard chemotaxis assays (14, 27, 49 -51) . Potency differences could be due to eotaxin and eotaxin-2 having higher affinities for CCR3 than MCP-4 and RANTES (14, 52) . It is also possible that eotaxin and eotaxin-2 have more efficient signaling (i.e., higher "intrinsic activity") than MCP-4 and RANTES or are relatively resistant to catabolism by CD26/dipeptidyl-peptidase IV (53, 54) . Alternatively, the ability of MCP-4 and RANTES to bind to other chemokine receptors may have a dampening effect on TEM. To date, eosinophils have been found to express CCR1 and CCR3 and in some cases CXCR1 and CXCR2 (44) . Thus far, CCR2 has not been detected on eosinophils. Preincubation of eosinophils with the 7B11 anti-CCR3 Ab and continued exposure to the Ab during the TEM assay completely abolished chemokine-induced eosinophil TEM, indicating that eotaxin, MCP-4, and RANTES selectively recruit eosinophils by engaging the CCR3 receptor. Several investigators have shown inhibition of eosinophil chemotaxis to C-C chemokines and changes in calcium flux using the same Ab to CCR3 (44, 55) .
We observed that IL-1␤ was significantly (100-to 1000-fold) more potent than TNF-␣ in inducing TEM of eosinophils. Neither TNF-␣ nor IL-1␤ has been found to be directly chemotactic for eosinophils across endothelial barrier (56) . However, previous studies have demonstrated increased eosinophil TEM across HUVEC activated with IL-1␤; this response is inhibited by Abs against ␤1 and ␤2 integrins or with a combination of anti-ICAM-1, anti-E-selectin, and anti-VCAM-1 (8, 19, 20) . In addition to inducing adhesion molecules, these cytokines also induce the release of other cytokines, including GM-CSF and RANTES (57) (58) (59) . GM-CSF is known to be chemokinetic for eosinophils, and previous studies have shown that ϳ50% of the eosinophil TEM response to IL-1␤ is inhibited by an Ab to GM-CSF, indicating that FIGURE 6. Effect of the anti-CCR3 Ab 7B11 on eotaxin-induced eosinophil TEM across TNF-␣-activated HUVEC. Endothelial cells were grown as a monolayer in Transwell inserts, stimulated for 4 h with either enriched medium (control) or 25 ng/ml of TNF-␣, and rinsed. 51 Cr-labeled eosinophils were preincubated with medium, anti-CCR3 Ab (10 g/ml), or anti-HLA Ab (negative control) at 4°C for 30 min and then were placed in the upper chamber. Medium control or eotaxin (10 ng/ml) was added to the lower chamber. Eosinophil TEM was determined as in Fig. 1 . Data shown represent mean Ϯ SEM from three experiments in which control migration was 3.7 Ϯ 0.3%. ‫,ء‬ p Ͻ 0.05 vs control.
FIGURE 7.
Effect of the blocking mAb against VLA-4, ␣D␤2, and PE-CAM-1 on eotaxin-induced eosinophil TEM across TNF-␣-activated HUVEC. Endothelial cells were grown as a monolayer in Transwell inserts, stimulated for 4 h with either enriched medium (control) or 25 ng/ml of TNF-␣, and rinsed. A, 51 Cr-labeled eosinophils were preincubated with medium, anti-VLA-4 Ab (2 g/ml), anti-␣D␤ 2 (220 g/ml), or anti-HLA Ab (negative control) at 4°C for 30 min and then were placed in the upper chamber. B, Medium or TNF-␣-stimulated HUVEC was treated with medium, anti-PECAM Ab (10 g/ml), or 12D10 (negative control) at 37°C for 30 min, and then 51 Cr-labeled eosinophils were placed in the upper chamber. Medium control or eotaxin (10 ng/ml) was added to the lower chamber. Eosinophil TEM was determined as in Fig. 1 . Data shown represent mean Ϯ SEM from three experiments in which control migration was 4.0 Ϯ 0.6%. ‫,ء‬ p Ͻ 0.05 vs control.
IL-1␤ induction of GM-CSF production by HUVEC is involved in the response (9) . The difference between IL-1␤ and TNF-␣ in inducing eosinophil TEM could be due to their potency in generating GM-CSF from HUVEC. IL-1␤ is more potent than TNF-␣ in this regard (60) . However, TEM induced by TNF-␣ or IL-5 was probably independent of endothelial-derived chemokines because the presence of anti-CCR3 or anti-CCR1 (data not shown) did not inhibit eosinophil TEM by any of these cytokines in the absence of added chemokine.
Synergism between IL-1␤ or TNF-␣ with RANTES or eotaxin in inducing eosinophil TEM is a distinctive finding of this study. Activation of endothelial cells by these proinflammatory cytokines results in induction of ICAM-1, VCAM-1, and E-selectin together with GM-CSF and RANTES, which could enhance eosinophil adhesion and transmigration in the presence of chemokine on the basal side of the monolayer. Abs directed to ␣D␤ 2 or VLA-4 had no effect on TEM induced by eotaxin alone or in the presence of TNF-␣, suggesting that their ligands such as VCAM-1 and ICAM-3 are not involved in the response. PECAM-1 has previously been shown to participate in TEM of monocytes (61) . Interestingly, a specific Ab directed against PECAM-1 failed to inhibit eotaxin-induced TEM but completely inhibited the increase of TEM induced by TNF-␣ when combined with eotaxin. This suggests that eotaxin-induced TEM is independent of PECAM-1 but that the synergistic response induced by TNF-␣ with eotaxin requires participation of PECAM-1.
Preincubation of eosinophils with IL-5 significantly enhanced RANTES-and eotaxin-induced TEM across resting HUVEC, confirming and extending our previous findings (18) . In addition, the results also indicate a clear synergy between IL-5 and eotaxin (Table I) and among IL-1␤, IL-5, and eotaxin. A similar synergy between IL-5 and eotaxin has been recently reported in tissue eosinophilia in animal models (39, 62) . We observed a less than additive response using IL-1␤ and IL-5. The lack of synergy between IL-1␤ and IL-5 is not surprising in light of the fact that IL-1-activated HUVEC produce GM-CSF, which has an activity similar to that of IL-5 on eosinophils (see above). Taken together, these results suggest that maximal eosinophilia will occur in a tissue in which endothelial activators, eosinophil priming cytokines, and eosinophil-active chemokines are expressed simultaneously.
The findings in the present study have numerous implications for the mechanism of eosinophil recruitment as well as therapeutic strategies for disrupting this process. The observation of greater eosinophil TEM with selective CCR3 agonists (eotaxin and eotaxin-2) than nonselective agonists (RANTES and MCP-4) suggests that receptors other than CCR3 may dampen the response to RANTES or MCP-4 (e.g., CCR1 or CCR2). It is possible that receptors on endothelium can modify the response. In a separate study we found that HUVEC express CCR3, CCR4, CCR5, and CXCR4 (63, 64) . Thus, differential responses to chemokines on the part of the endothelial cells may influence the outcome of the response. The potential role of these chemokine receptors either in endothelial responses or posssibly as chemokine presentation molecules is a subject currently under investigation. Our results may also be explained by difference in intrinsic activity of the chemokines involved. Recent studies by Farzan et al. (65) and Oppermann et al. (66) have shown a dissociation between activation of various signaling pathways (e.g., receptor binding affinity, calcium signals vs protein tyrosine kinase activation) among chemokines binding to the same receptor. Chemokine responses are now known to be influenced by glycosylation of the agonist as well as by the state of chemokine receptor tyrosine sulfation (65) . The differential ability of chemokines to induce receptor activation, phosphorylation, desensitization, and internalization may provide yet another mechanism for the agonist-induced attenuation of chemokine receptor signaling (66) . Further studies are needed to better understand the potency and efficacy differences between eotaxin/ eotaxin-2 and RANTES/MCP-4 in inducing eosinophil TEM.
Huber et al. (67) found that IL-1␤-induced TEM of neutrophils is dependent on endothelial-derived IL-8. The failure of anti-CCR3 to inhibit eosinophil TEM induced by TNF-␣ or IL-5 indicates that TNF-activated endothelial cells are not producing CCR3 agonists that are involved in the TEM response in vitro. Because there was a trend of anti-CCR3-dependent inhibition of eosinophil TEM across IL-1␤-treated HUVEC, the role of chemokines in the IL-1 response remains uncertain. These findings also imply that the clinical efficacy of CCR3 antagonists in the therapy of allergic inflammation may be limited in cases in which the inflammatory response is heavily driven by the production of IL-5 or endothelial activators, particularly TNF-␣. In such a case, our findings indicate that the TEM response is mediated independently of CCR3. However, on a more encouraging note is the finding that anti-CCR3 profoundly inhibited the response induced by the combination of a chemokine with an endothelial activator, IL-5, or both. Because this is likely to be the cytokine mixture found in vivo, clinical studies with CCR3 antagonists are clearly warranted. 
